Categories Analysis, Health Care

Pfizer (PFE): Declines in COVID-19 products expected to drag down overall revenue in 2023

Adjusted EPS for the year is expected to be $3.25-3.45

Shares of Pfizer Inc. (NYSE: PFE) were down on Tuesday despite the company delivering better-than-expected results for the first quarter of 2023. The stock has dropped 24% year-to-date. The company expects revenues in 2023 to be lower than the previous year due to anticipated declines in COVID-19 products.

Quarterly performance

Pfizer’s revenues decreased 29% year-over-year to $18.3 billion in Q1 2023, mainly due to a drop in Comirnaty revenues worldwide. Revenues declined 26% on an operational basis. Excluding the contributions from its COVID-19 products, overall revenues grew 5% operationally.

GAAP EPS was $0.97, down 29% YoY while adjusted EPS decreased 24% to $1.23. Despite the YoY declines, both the top and bottom line numbers surpassed expectations.

COVID-19 products

In Q1 2023, revenues from Pfizer’s COVID-19 products Comirnaty and Paxlovid were $7.1 billion. Comirnaty revenues were down 75% operationally from last year, mainly due to lower contracted deliveries and demand in international markets.

Paxlovid revenues increased, helped by the favorable timing of a final delivery related to the US government contract, along with strong demand in China, and launches in certain international markets.

For fiscal year 2023, Pfizer expects Comirnaty revenues of approx. $13.5 billion, down 64% YoY and Paxlovid revenues of approx. $8 billion, down 58% YoY. This guidance is no longer based on expected deliveries under supply contracts but includes anticipated sales through traditional commercial markets in the US in the latter half of the year.

Seagen acquisition

Pfizer has entered into an agreement to acquire Seagen, a biotechnology company that develops oncology medicines. The addition of Seagen’s antibody-drug conjugate (ADC) technology to its portfolio is expected to increase Pfizer’s capabilities in oncology significantly. Pfizer expects this acquisition could contribute over $10 billion in risk-adjusted revenues in 2030, with significant growth potential ahead.

Outlook

For FY2023, Pfizer expects total revenues to decline 29-33% YoY to $67-71 billion, due to expected revenue declines for its COVID-19 products. The company expects sales contributions from its COVID products to be significantly lower in the second quarter versus the first quarter. Excluding the COVID-19 products, revenues are expected to be up 7-9% operationally. Adjusted EPS for the year is expected to decline 48-51% YoY to a range of $3.25-3.45.

Most Popular

BLK Earnings: BlackRock Q2 2024 profit jumps on higher revenues

Asset management company BlackRock, Inc. (NYSE: BLK) on Monday reported a double-digit increase in adjusted profit for the second quarter of 2024, aided by an 8% increase in revenues. Second-quarter

GS Earnings: All you need to know about Goldman Sachs’ Q2 2024 earnings results

The Goldman Sachs Group, Inc. (NYSE: GS) reported its second quarter 2024 earnings results today. Net revenues were $12.73 billion, up 17% compared to the same period a year ago,

Intuitive Surgical likely to report strong revenue, profit growth for Q2 2024

Intuitive Surgical, Inc. (NASDAQ: ISRG) is expected to report its second-quarter earnings next week, amid expectations for strong revenue and profit growth. The medical device maker is thriving on the

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top